Skip to main content
. 2019 Jun 25;57(7):e01834-18. doi: 10.1128/JCM.01834-18

FIG 3.

FIG 3

Failure rate based on A2143G and/or A2142G mutations. In our group of 58 patients with follow-up results, subjects with one of these mutations were significantly more likely to fail treatment than those with unmutated 23S rRNA (P < 0.001): 87.5% of patients who failed therapy, as opposed to only 9.5% in the eradicated group.